Key Takeaways:
-Osimertinib significantly improved PFS in unresectable, stage III NSCLC with EGFR mutations post-chemoradiotherapy.
-Median PFS was 39.1 months for osimertinib versus 5.6 months for placebo.
-Objective response rate and disease control rate were higher with osimertinib.
-Safety profile showed higher rates of adverse events in the osimertinib arm, but benefits in PFS were substantial.
